Pharmacokinetics Profile Study of BG00012 Standard Formulation and BG00012 Active Pharmaceutical Ingredient

Inclusion criteria

• Males 18 to 55 years old, inclusive, at the time of informed consent.
• Must weigh between 50 kg and 110 kg, inclusive.
• Must have a body mass index (BMI) between 19 kg/m2 and 30 kg/m2, inclusive.
• All subjects must practice effective contraception during the study and be willing and able to continue contraception for 30 days after their last dose of study treatment.
• Must be a non-smoker, and no use of chewing tobacco, for at least 6 months prior to Day -1.
• Must have a screening physical examination and ECG without any clinically significant abnormality (as determined by the Investigator).

Exclusion criteria

• History of malignancy (subjects with basal cell carcinoma that has been completely excised prior to study entry remain eligible).
• History of severe allergic or anaphylactic reaction.
• History of any clinically significant endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, and renal, or other major diseases, as determined by the Investigator.
• Clinically significant abnormal hematology or blood chemistry values, as determined by the Investigator.
• Serious infection (e.g., pneumonia, septicemia) within the 2 months prior to Day -1.